Compare ROMA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | XOMA |
|---|---|---|
| Founded | 2018 | 1981 |
| Country | Hong Kong | United States |
| Employees | N/A | 14 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 471.6M |
| IPO Year | 2022 | N/A |
| Metric | ROMA | XOMA |
|---|---|---|
| Price | $8.11 | $41.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $52.50 |
| AVG Volume (30 Days) | 46.0K | ★ 91.2K |
| Earning Date | 12-23-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $22.29 |
| 52 Week High | $11.77 | $42.81 |
| Indicator | ROMA | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 59.80 |
| Support Level | $6.01 | $37.00 |
| Resistance Level | $8.53 | $42.25 |
| Average True Range (ATR) | 0.96 | 0.36 |
| MACD | 0.12 | -0.16 |
| Stochastic Oscillator | 55.48 | 48.48 |
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.